Diffusion Pharmaceuticals Analyst Ratings
Diffusion Pharmaceuticals Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/16/2022 | 38.28% | HC Wainwright & Co. | → $9.5 | Upgrades | Neutral → Buy |
11/17/2020 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
11/17/2020 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
12/18/2019 | -49.05% | HC Wainwright & Co. | $10 → $3.5 | Reiterates | → Buy |
03/21/2018 | -81.8% | HC Wainwright & Co. | → $1.25 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
---|---|---|---|---|---|
08/16/2022 | 38.28% | HC Wainwright公司 | →$9.5 | 升級 | 中性→購買 |
11/17/2020 | - | HC Wainwright公司 | 評級下調 | 購買→中性 | |
11/17/2020 | - | HC Wainwright公司 | 評級下調 | 購買→中性 | |
2019年12月18日 | -49.05% | HC Wainwright公司 | $10→$3.5 | 重申 | →購買 |
2018年03月21日 | -81.8% | HC Wainwright公司 | →$1.25 | 開始承保 | →購買 |
Diffusion Pharmaceuticals Questions & Answers
擴散藥品問答
The latest price target for Diffusion Pharmaceuticals (NASDAQ: DFFN) was reported by HC Wainwright & Co. on August 16, 2022. The analyst firm set a price target for $9.50 expecting DFFN to rise to within 12 months (a possible 38.28% upside). 1 analyst firms have reported ratings in the last year.
擴散製藥(納斯達克:DFFN)的最新目標價是由HC Wainwright&Co.於2022年8月16日報道的。這家分析公司將目標價定為9.50美元,預計DFFN將在12個月內上漲至38.28%。1家分析公司在過去一年公佈了評級。
The latest analyst rating for Diffusion Pharmaceuticals (NASDAQ: DFFN) was provided by HC Wainwright & Co., and Diffusion Pharmaceuticals upgraded their buy rating.
擴散製藥(納斯達克代碼:DFFN)的最新分析師評級由HC Wainwright&Co.提供,擴散製藥上調了買入評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Diffusion Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Diffusion Pharmaceuticals was filed on August 16, 2022 so you should expect the next rating to be made available sometime around August 16, 2023.
分析師在進行了廣泛的研究後得出了股票評級,其中包括查閱公共財務報表,與擴散製藥公司的高管和客戶交談,以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。擴散製藥的上一次評級是在2022年8月16日提交的,所以你應該預計下一次評級將在2023年8月16日左右提供。
While ratings are subjective and will change, the latest Diffusion Pharmaceuticals (DFFN) rating was a upgraded with a price target of $0.00 to $9.50. The current price Diffusion Pharmaceuticals (DFFN) is trading at is $6.87, which is within the analyst's predicted range.
雖然評級是主觀的,並將發生變化,但最新的擴散製藥(DFFN)評級被上調,目標價為0.00美元至9.50美元。擴散製藥(DFFN)目前的交易價格為6.87美元,在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。